title: DPP-4 Inhibitor Teneligliptin Improves Insulin Resistance and Serum Lipid Profile in Japanese Patients with Type 2 Diabetes.
abstract: Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to improve the glycemic control and blood hemoglobin A1c (HbA1c) concentrations. However, there are few reports as yet suggesting that DPP-4 inhibitors may also improve insulin resistance and the serum lipid profile in the clinical setting. This study was aimed at investigating the effect of 14-week treatment with teneligliptin (20 mg/day) on the homeostasis model assessment ratio (HOMA-R), an indicator of insulin resistance, and serum lipid profile in 9 patients with type 2 diabetes. The treatment produced a significant decrease of the blood glucose and HbA1c concentration (blood glucose: p=0.008; HbA1c: p=0.038), and also improved HOMA-R (p=0.039). Furthermore, the patients showed elevation of the serum HDL-cholesterol level (p=0.032), and a tendency towards reduction of the serum triglyceride level. The results indicate that teneligliptin acts not only to improve the blood glucose control, but also to improve the insulin resistance and serum lipid profile in Japanese type 2 diabetes patients.
authors.affiliation: Department of Internal Medicine, Medical Clinic, Aichi Medical University, Nagoya, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Kusunoki
authors.affiliation: Department of Biomedical Information Engineering, Graduate School of Medical Science, Yamagata University, Yamagata, Japan.
authors.forename: D
authors.initials: D
authors.lastname: Sato
authors.affiliation: Department of Biomedical Information Engineering, Graduate School of Medical Science, Yamagata University, Yamagata, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nakamura
authors.affiliation: Research Center of Health, Physical Fitness and Sports, Nagoya University, Nagoya, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Oshida
authors.affiliation: Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Tsutsui
authors.affiliation: Department of Sports Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Natsume
authors.affiliation: Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Tsutsumi
authors.affiliation: Vascular Center, Sanno Medical Center, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Miyata
mesh_terms: D000368:Aged; D044466:Asian People; D001786:Blood Glucose / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D053778:Thiazolidines / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008055:Lipids; D011720:Pyrazoles; D053778:Thiazolidines; C579035:3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine